UroGen Pharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell UroGen Pharma and other ETFs, options, and stocks.About URGN
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology.
CEOElizabeth Barrett
CEOElizabeth Barrett
Employees235
Employees235
HeadquartersPrinceton, New Jersey
HeadquartersPrinceton, New Jersey
Founded2004
Founded2004
Employees235
Employees235
URGN Key Statistics
Market cap779.09M
Market cap779.09M
Price-Earnings ratio-5.14
Price-Earnings ratio-5.14
Dividend yield—
Dividend yield—
Average volume1.24M
Average volume1.24M
High today$17.40
High today$17.40
Low today$16.71
Low today$16.71
Open price$17.04
Open price$17.04
Volume551.94K
Volume551.94K
52 Week high$21.71
52 Week high$21.71
52 Week low$3.42
52 Week low$3.42
URGN News
Simply Wall St 1d
UroGen Pharma Ltd.'s Price Is Out Of Tune With RevenuesIt's not a stretch to say that UroGen Pharma Ltd.'s ( ) price-to-sales (or "P/S") ratio of 8.5x right now seems quite "middle-of-the-road" for companies in the...
TipRanks 5d
UroGen Pharma announces publication of development program for ZUSDURIUroGen Pharma (URGN) announced the publication of a comprehensive review of the clinical development program for ZUSDURI for intravesical solution, formerly kno...
TipRanks 6d
Promising Developments and Market Potential Drive Buy Rating for Urogen Pharma’s ZusduriAnalyst Tara Bancroft from TD Cowen reiterated a Buy rating on Urogen Pharma and keeping the price target at $35.00. Elevate Your Investing Strategy: Take advan...
Analyst ratings
88%
of 8 ratingsBuy
87.5%
Hold
12.5%
Sell
0%
People also own
Based on the portfolios of people who own URGN. This list is generated using Robinhood data, and it’s not a recommendation.